 I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China National Medical Products Administration NMPA has accepted its pivotal trial application for eftansomatropin also known as TJ101 as a weekly treatment for growth hormone deficiency in pediatric patients PGHD. 